Current clinical understanding and effectiveness of portopulmonary hypertension treatment

Current clinical understanding and effectiveness of portopulmonary hypertension treatment

Portopulmonary hypertension (PoPH) is a rare subtype of Group 1 pulmonary arterial hypertension (PAH) with a poor prognosis. According to the most up-to-date definition, PoPH is characterized by a mean pulmonary arterial pressure (PAP) of >20 mmHg at rest, a pulmonary artery wedge pressure of...

Full description

Bibliographic Details
Main Authors:	Yuichi Tamura, Yudai Tamura, Yu Taniguchi, Masanori Atsukawa
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-04-01
Series:	Frontiers in Medicine
Subjects:	portopulmonary hypertension treatment endothelin receptor antagonist liver transplantation pulmonary arterial hypertension screening
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2023.1142836/full

Similar Items

Current Therapy and Liver Transplantation for Portopulmonary Hypertension in Japan
by: Katsutoshi Tokushige, et al.
Published: (2023-01-01)

How do the 2022 European Society of Cardiology/European Respiratory Society guidelines modify the diagnosis of portopulmonary hypertension in patients with cirrhosis complicated by portal hypertension? A post hoc analysis
by: Masanori Atsukawa, et al.
Published: (2023-08-01)

Portopulmonary hypertension: state of the art
by: Mateo Porres-Aguilar, et al.
Published: (2008-10-01)

Portopulmonary Hypertension: From Bench to Bedside
by: Christopher Thomas, et al.
Published: (2020-11-01)

Treatment pattern and clinical outcomes in portopulmonary hypertension: A database study in Japan
by: Masanori Atsukawa, et al.
Published: (2022-11-01)

Portopulmonary hypertension: Current developments and future perspectives
by: Huawei Xu, et al.
Published: (2022-03-01)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Portopulmonary hypertension
by: Sarfraz Saleemi, et al.
Published: (2014-01-01)

Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview
by: Jose T. Altamirano, et al.
Published: (2012-09-01)

The early outcomes of candidates with portopulmonary hypertension after liver transplantation
by: Bingsong Huang, et al.
Published: (2018-06-01)

The portopulmonary hypertension: an overview from diagnosis to treatment
by: Andrea Salzano, et al.
Published: (2015-11-01)

Evaluation of Predisposing Metabolic Risk Factors for Portopulmonary Hypertension in Patients with NASH Cirrhosis
by: Türker F, et al.
Published: (2022-01-01)

Portopulmonary hypertension: Success with combined medical treatment
by: María Hernández, et al.
Published: (2023-04-01)

Current status of bosentan for treatment of pulmonary hypertension
by: Raja Shahzad, et al.
Published: (2008-01-01)

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies
by: Nick H. Kim, et al.
Published: (2024-01-01)

Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review
by: Niuniu Li, et al.
Published: (2023-08-01)

Bosentan use in pulmonary arterial hypertension: Russian and foreign experience
by: Z S Valieva, et al.
Published: (2017-08-01)

Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension
by: Monaco TJ, et al.
Published: (2016-05-01)

The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension
by: S N Avdeev
Published: (2016-07-01)

Congenital Absence of the Portal Vein as a Rare Cause of Portopulmonary Hypertension—A Case Study Series
by: Tereza Hlavata, et al.
Published: (2022-10-01)

Pulmonary vascular complications in portal hypertension and liver disease: A concise review
by: M. Porres-Aguilar, et al.
Published: (2013-01-01)

Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment
by: O A Arkhipova, et al.
Published: (2018-06-01)

Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment
by: Arkhipova O.A., et al.
Published: (2018-05-01)

Bosentan therapy for chronic thromboembolic pulmonary hypertension
by: L Huber, et al.
Published: (2007-10-01)

Portopulmonary hypertension caused by portal hypertension that is complicated by central diabetes insipidus
by: Tingting Zhao, et al.
Published: (2020-03-01)

Long‐term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension
by: Yuichi Tamura, et al.
Published: (2022-01-01)

Approaches to therapy for pulmonary hypertension: Role of the endothelin receptor antagonist bosentan
by: S N Avdeev
Published: (2015-09-01)

Long term survival of a biliary atresia patient by repeated liver transplantations for portopulmonary hypertension in addition to the hepatopulmonary syndrome
by: Shintaro Hayashida, et al.
Published: (2023-02-01)

Symptom‐based portopulmonary hypertension screening questionnaire in Japanese patients with chronic liver disease
by: Shun‐Ichi Wakabayashi, et al.
Published: (2023-08-01)

Current management of pulmonary arterial hypertension
by: Patrick Yerly, et al.
Published: (2016-05-01)

First clinical experience with endothelin receptor antagonist bosentan used in patients with pulmonary hypertension: results of a one-year study
by: S N Avdeev, et al.
Published: (2013-03-01)

Role of the endothelin receptor antagonist bosentan in the treatment of patients with pulmonary hypertension
by: N A Tsareva
Published: (2013-12-01)

Pulmonary hypertension: reasonable selection of specific therapy
by: N A Karoli, et al.
Published: (2018-03-01)

Role of echocardiography in screening for portopulmonary hypertension in liver transplant candidates: a meta-analysis
by: Xin Yin, et al.
Published: (2020-05-01)

Insights into Endothelin Receptors in Pulmonary Hypertension
by: Ruiqi Liu, et al.
Published: (2023-06-01)

Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going
by: Andreas Haryono, et al.
Published: (2022-05-01)

Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
by: M. Delcroix, et al.
Published: (2009-12-01)

Lower doses of bosentan in combination with sildenafil might be beneficial in pulmonary arterial hypertension
by: Ahmad Amin, et al.
Published: (2015-01-01)

Perioperative management with phosphodiesterase type 5 inhibitor and prostaglandin E1 for moderate portopulmonary hypertension following adult-to-adult living-donor liver transplantation: a case report
by: Takashi Onoe, et al.
Published: (2018-02-01)

A clinical case of long-term macitentan therapy in a female patient with idiopathic pulmonary hypertension
by: O A Arkhipova, et al.
Published: (2016-12-01)

Case report: Pathological differences in pulmonary arterial hypertension in long-term responders to calcium channel blockers
by: Yuichi Tamura, et al.
Published: (2023-11-01)